The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-14. Anything still debated is marked as such rather than presented as settled.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
| Property | Value | Notes |
|---|---|---|
| 外观 | 白色至类白色冻干粉 | 可能具吸湿性 |
| 溶解性 | 溶于水和水性缓冲液 | 典型肽类行为 |
| 冻干粉储存 | -20°C 或 2-8°C，避光 | 长期稳定性较好 |
| 复溶后储存 | 2-8°C，短期 | 避免反复冻融 |
| 常用分析 | RP-HPLC 与 LC-MS | 纯度与身份确认 |
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Chloramphenicol is available as a capsule or as a liquid. In some countries, it is sold as chloramphenicol palmitate ester (CPE). CPE is inactive, and is hydrolysed to active chloramphenicol in the small intestine. No difference in bioavailability is noted between chloramphenicol and CPE. Manufacture of oral chloramphenicol in the U.S. stopped in 1991, because the vast majority of chloramphenicol-associated cases of aplastic anaemia are associated with the oral preparation. No oral formulation of chloramphenicol is available in the U.S. for human use.
== Discovery == The N-acetylmuramoyl-L-alanine amidase enzymatic activity was first observed in human and mouse serum in 1981 by Branko Ladešić and coworkers. The enzyme (abbreviated NAMLAA) was then purified from human serum by this and other groups. The sequence of 15 N-terminal amino acids of NAMLAA was identified, but the cDNA for the protein was not cloned and the gene encoding NAMLAA was not known. In 2000, Dan Hultmark and coworkers discovered a family of 12 Peptidoglycan Recognition Protein (PGRP) genes in Drosophila melanogaster and by homology searches of available human and mouse sequences predicted the presence of long forms of human and mouse PGRPs, which they named PGRP-L by analogy to long forms of insect PGRPs. In 2001, Roman Dziarski and coworkers discovered and cloned three human PGRPs, named PGRP-L, PGRP-Iα, and PGRP-Iβ (for long and intermediate size transcripts), and established that human genome codes for a family of 4 PGRPs: PGRP-S (short PGRP) and PGRP-L, PGRP-Iα, and PGRP-Iβ. Subsequently, the Human Genome Organization Gene Nomenclature Committee changed the gene symbols of PGRP-S, PGRP-L, PGRP-Iα, and PGRP-Iβ to PGLYRP1 (peptidoglycan recognition protein 1), PGLYRP2 (peptidoglycan recognition protein 2), PGLYRP3 (peptidoglycan recognition protein 3), and PGLYRP4 (peptidoglycan recognition protein 4), respectively, and this nomenclature is currently also used for other mammalian PGRPs. Sergei Kiselev and coworkers also independently cloned mouse PGLYRP2 (which they named TagL).
distillation The process of separating the component substances of a liquid mixture by exploiting differences in the relative volatility of the mixture's components through selective boiling and subsequent condensation. The apparatus used to distill a substance is called a still, and the re-condensed substance yielded by the process is called the distillate.
Sources: en.wikipedia.org
=== Pharmacodynamics === Similarly to ketamine, norketamine acts as a noncompetitive NMDA receptor antagonist (Ki = 1.7 μM and 13 μM for (S)-(+)-norketamine and (R)-(–)-norketamine, respectively). Also, similarly again to ketamine, norketamine binds to the μ- and κ-opioid receptors. Relative to ketamine, norketamine is much more potent as an antagonist of the α7-nicotinic acetylcholine receptor, and produces rapid antidepressant effects in animal models which have been reported to correlate with its activity at this receptor. However, norketamine is about 1/5 as potent as ketamine as an antidepressant in mice as per the forced swim test, and this seems also to be in accordance with its 3–5-fold reduced comparative potency in vivo as an NMDA receptor antagonist. Norketamine's metabolites, dehydronorketamine (DHNK) and hydroxynorketamine (HNK), are far less or negligibly active as NMDA receptor antagonists in comparison, but retain activity as potent antagonists of the α7-nicotinic acetylcholine receptor. In 2024, norketamine was discovered to act as a highly potent positive allosteric modulator of the opioid receptors, including of the μ-opioid receptor (MOR). It shares this action with ketamine and hydroxynorketamine (HNK). They are all active in this action at very low concentrations, for instance 1 nM. Ketamine, norketamine, and HNK can potentiate the effects of endogenous opioids like met-enkephalin and exogenous opioids like morphine.
=== Legal status === In February 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hyftor, intended for the treatment of angiofibroma. The applicant for this medicinal product is Plusultra pharma GmbH. Hyftor was authorized for medical use in the European Union in May 2023. Sirolimus, as Rapamune solution, was approved for medical use in the United States in 1999; and as Rapamune tablets in August 2000. Sirolimus, as Fyarro, was approved for medical use in the United States in November 2021. Sirolimus, as Hyftor, was approved for medical use in the United States in March 2022.
=== Transgender Law Center === Transgender Law Center is a national trans-led organization founded in 2002, that is dedicated to advocate for the rights and well-being of transgender and gender nonconforming people with legal advocacy, policy initiatives, and community empowerment. Transgender Law Center expand their work to multiple important areas, including but not limited to, healthcare access, education, employment and housing. They advocate for better healthcare access for transgender people with multiple efforts. With policy advocacy and litigation efforts, Transgender Law Center advocates for laws and regulations to require insurance companies to cover gender-affirming care and engages in legal actions to fight against and challenge practices and policies that are discriminatory towards transgender people. Transgender Law Center also engages in public awareness campaigns and community engagements to ensure the significancy of transgender healthcare along with the barriers and unmet needs that are being advocated reflects real-world experiences, hoping to shift public perceptions and gain support for necessary changes to be made. For the professionals, Transgender Law Center provides education and trainings for healthcare providers and other professionals to make efforts into increasing awareness and promoting equal and competent care for transgender people. In effort to provide more resources, they address systemic challenges and organize guides and reports on best practices for transgender healthcare.
== Function == Unlike other members in the MIA gene family, MIA3 is broadly expressed, except in the cells belonging to the hematopoietic system. High levels of MIA3 expression are observed both in embryonic and adult tissues. MIA3 resides at the ER exit site and functions as a guide for loading the cargo molecule collagen VII into COPII carriers, which mediates the exit of secretory protein out of the ER with the help of cutaneous T-cell lymphoma–associated antigen 5 (cTAGE-5). A recent study indicates that MIA3 is also involved in the secretion of other collagens, including collagens I, II, III, IV, and IX, from chondrocytes, fibroblasts, endothelial cells, and mural cells, indicating its participation in chondrocyte maturation and bone mineralization. MIA3 has been suggested as a tumor suppressor in melanoma, colorectal cancer, and hepatoma, and induction of expression of MIA3 results in a significant decrease in motility and invasive potential. On the other hand, it has also been found that MIA3 promotes angiogenesis and lymphangiogenesis by upregulating platelet-derived growth factor beta (PDGF-b) polypeptide and neuropolin 2 in oral squamous cell carcinoma.
Sources: en.wikipedia.org
== Proposal of protein primary structure == Hofmeister argued for peptide bonds by process of elimination. C-C, ether and ester bonds were unlikely considering the digestion by trypsin. R=C-N-C=R bonds could be eliminated because it would imply a much larger number of carboxylate groups than is observed experimentally. Hofmeister also argued for peptide bonds based on the biuret reaction observed with all proteins but never with free amino acids. Since biuret has the formula NH2-CO-NH-CO-NH2, that suggested the presence of similar peptide bonds in proteins.
Unless the volume of a liquid exactly matches the volume of its container, one or more surfaces are observed. The presence of a surface introduces new phenomena which are not present in a bulk liquid. This is because a molecule at a surface possesses bonds with other liquid molecules only on the inner side of the surface, which implies a net force pulling surface molecules inward. Equivalently, this force can be described in terms of energy: there is a fixed amount of energy associated with forming a surface of a given area. This quantity is a material property called the surface tension, in units of energy per unit area (SI units: J/m2). Liquids with strong intermolecular forces tend to have large surface tensions. A practical implication of surface tension is that liquids tend to minimize their surface area, forming spherical drops and bubbles unless other constraints are present. Surface tension is responsible for a range of other phenomena as well, including surface waves, capillary action, wetting, and ripples. In liquids under nanoscale confinement, surface effects can play a dominating role since – compared with a macroscopic sample of liquid – a much greater fraction of molecules are located near a surface. The surface tension of a liquid directly affects its wettability.
He said the deal had been brokered through a partnership with private business and mediated by Secretary of State Marco Rubio and Secretary of Defense Pete Hegseth. Trump claimed that the agreement came "at no cost to the American taxpayer" and would more than double U.S. oil reserves. Few details were disclosed regarding the legal and financial structure of the agreement, including which fields or companies were involved, or how the United States would exercise majority control over the reserves. The Washington Post reported that under the arrangement the United States had gained a controlling stake in nearly a quarter of Venezuela's untapped oil reserves, becoming the majority owner of a newly formed joint venture holding 100-year contracts at the fields, and that a list of 17 oil fields in which the United States would take a stake had circulated before the announcement. According to deal points reviewed by the newspaper, the United States government's stake would be split between equity ownership and guarantees that it would purchase oil produced by the venture at cost to refill the Strategic Petroleum Reserve. Several of the fields lacked infrastructure or access to transport hubs, and those where such infrastructure existed had suffered years of neglect and theft of machinery; the newspaper reported that it was unclear who would make the tens of billions of dollars of investment needed before oil could be pumped, major oil companies having largely regarded such spending as too risky.
identify metabolic disease signatures assess treatment class (pre- or post-treatment) identify compounds present in a patient sample that may alter drug response, or be caused by a therapy identify metabolite variables and interactions among these variables map identified variables to known metabolic and biochemical pathways
== History == 4-HO-DPT was first described in the scientific literature by David Repke and colleagues in 1977. Subsequently, it was described in further detail by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). The drug was encountered as a novel designer drug in Europe in 2012.
Sources: en.wikipedia.org
反相高效液相色谱用于分离和纯度评估，质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。
高温、强光、潮湿和反复冻融都会加速肽降解。冻干粉通常建议低温避光保存。复溶后的溶液稳定性较短，应依据验证数据确定保存条件。
氧化、脱酰胺和截短肽可能影响色谱纯度和生物活性读数。不同批次之间这些杂质的相对比例可能不同。是否具有临床意义取决于杂质水平、给药途径和暴露量，尚无统一阈值。
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。